Menaquinone-7 as a novel pharmacological therapy in the treatment of rheumatoid arthritis: A clinical study

What Was Tested

This randomized controlled trial paper looks at Vitamin D, K2, Magnesium and Zinc in the context of rheumatoid arthritis.

Menaquinones (MKs) have been reported to induce apoptosis in rheumatoid arthritis (RA) synovial cells.

Recently, menaquinone-4 (MK-4) was proven as a new potential agent for the treatment of RA.

Who Took Part

The abstract describes 84 patients taking part.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

In a cross sectional study, 84 RA patients (24 male, 60 female) (average age=47.2 years) were enrolled in this study.

The clinical and biochemical markers on RA patients treated with MK-7 and naïve group were assessed.

How the Study Was Run

The researchers set it up as a randomized study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

What Was Measured

The subject headings attached to it are Antirheumatic Agents, Arthritis, Rheumatoid, Biomarkers, Blood Sedimentation, Capsules, Cross-Sectional Studies and Disability Evaluation.

The authors tagged it with the keywords DAS28-ESR, Matrix metalloproteinase., Menaquinone-7, Rheumatoid arthritis and ucOC.

What This Means in Plain Language

The paper is a randomized study of Vitamin D, K2, Magnesium and Zinc in 84 patients in people with rheumatoid arthritis.

The publication is from 2015 (European journal of pharmacology), a journal based in Netherlands.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Rheumatoid arthritis research.